From: Entrevestor
Date: Feb.18, 2026
ABK Biomedical late last year raised US$35 million (C$47.9 million) in a Series D financing round to support clinical trials, manufacturing expansion and development of a product to be used in treating liver cancer.
The Halifax-based medical device company said the oversubscribed round was led by J.P. Morgan Life Sciences Private Capital, investing in the company for the first time.
A stalwart of the Halifax life sciences community, ABK Biomedical has been one of the most successful companies in the region at attracting venture capital. It previously closed rounds worth US$30 million in both 2022 and 2019, and C$9 million in 2017.